Northwind Genetics

RARE-007 · X-linked hypophosphatemia in adults

Phase 3EnrollingRare diseaseAt risk

Executive summary

Pivotal Ph3 placebo-controlled study. Enrolment is critically behind (41% vs 65% planned) and a Type B FDA meeting is scheduled to discuss sample-size re-estimation. EAC has breached the contracted budget.

Phase

Phase 3

Stage

Enrolling

Health

At risk

Milestone timeline

Showing completed, in-progress, and at-risk milestones. Planned future milestones are omitted from the sponsor view.

Mar 1, 2024forecast end Aug 30, 2028

FPI
Apr 18, 2024
Complete
50% enrolment
Dec 15, 2025
In progress
75% enrolment
Aug 20, 2026
At risk
LPI
Feb 15, 2027
At risk

Signed deliverables

Updated live as deliverables are signed.

Essential Documents
filed and signed
Audit Trail
green
CSR draft
not yet released to sponsor

Request an update

Ask for a status update, request a document, or submit a question. The study lead is notified and you’ll see the response in this portal.